Program
fluticasone furoate
Also written as “GW685698X”, “FF/UMEC/VI” and “Fluticasone furoate”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, led by 4 companies.
Drug pageFluticasone furoate: every studyAll 105 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 942 open or running | phase 4since Feb 14, 2007 | Feb 8, 2005 | Jan 26, 2027phase 3 · NCT05757102 |
| Novartisits history only | 10 open or running | phase 3since Jan 17, 2011 | Jan 17, 2011 | none ahead |
| ORAits history only | 10 open or running | phase 4since Feb 24, 2010 | Feb 24, 2010 | none ahead |
| Sandoz | 10 open or running | phase 3since Oct 15, 2025 | Oct 15, 2025 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sandoz only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2025First study: phase 3 study in RespiratoryFirst studyNCT07223294
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study Sandoz leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223294Respiratory | 3 | Withdrawn | Apr 21, 2026 | 0 |
How it is read
Names in the registry
- “GW685698X”, 16 entries
- “FF/UMEC/VI”, 9 entries
- “Fluticasone furoate”, 8 entries
- “FF”, 6 entries
- “Fluticasone Furoate”, 5 entries
Codes read as this program: GW685698.
Conditions, from the studies’ own filings
- Asthma, 44 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Rhinitis, Allergic, Perennial, 15 studies
- Rhinitis, Allergic, Seasonal, 9 studies
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.